ULTRASOUND AND MALIGNANT TRANSFORMATION IN VITRO

超声与体外恶性转化

• 批准号: 3179890
• 负责人: GEORGE H HARRISON
• 金额: $ 9.48万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 1985
• 资助国家: 美国
• 起止时间: 1985-07-01 至 1990-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3179890
• 关键词: X ray; benzopyrenes; bioassay; cancer risk; ionizing radiation; particle beam; phorbols; physical chemical interaction; radiation carcinogenesis; radiation sensitivity; tissue /cell culture; tumor promoters; ultrasound biological effect

We propose to assess the oncogenic risk of ultrasound, using the C3H/10T1/2 in vitro assay for malignant transformation. This assay is a more direct and quantitative measure of oncogenic risk than are assays of mutation or chromosomal alterations. Pulsed ultrasonic beams configured to simulate diagnostic conditions will be used to irradiate cells alone, in combination with carcinogenic treatment, or followed by post-treatment culturing in 0.1 /g/ml of 12-0-tetradecanoyl-phorbol-13-acetate (TPA) in order to investigate the possible oncogenic interaction of co-stressors and tumor promotors with ultrasound. In examining the effect of ultrasound alone, experiments will be designed to detect a malignant transformation rate equivalent to or greater than the response of 1 Gy of 250 kVp X-rays or to about 2 /g/ml of benzo(a)pyrene, with 95% statistical confidence above the spontaneous transformation rate. In examining the effect of ultrasound as a co-stressor, experiments will be designed to detect a two-fold enhancement of transformation by ultrasound with 95% statistical confidence. Cells will be insonated in suspension in a transmission chamber at 37 degrees C using uniform, minimally focussed beam profiles, with insonation parameters simulating the upper range of pressure amplitudes from clinical ultrasonic imaging and doppler systems. Emphasis will be placed on providing replicable, well-characterized ultrasound delivery and bioassay.

我们建议评估超声的致癌风险，使用 恶性转化的C3 H/10 T1/2体外试验。 这 检测是一种更直接和定量的致癌风险测量方法 而不是突变或染色体改变的检测。 脉冲 被配置为模拟诊断条件的超声波束将 单独用于照射细胞，与致癌物质组合 处理，或随后在0.1 /g/ml的 12-0-十四酰基-佛波醇-13-乙酸酯（TPA），以 研究共应激子可能的致癌相互作用， 肿瘤促进剂。 在检查超声波单独的效果，实验将是 设计用于检测恶性转化率， 或大于1戈伊的250 kVp X射线的响应，或 苯并（a）芘约2 /g/ml，统计置信度为95% 高于自发转化率。 同代表们一起审议 超声作为共应激源的作用，将设计实验 通过超声波检测到转化的两倍增强， 95%的统计置信度。 细胞会被声波照射 悬浮在37摄氏度的传输室中， 均匀的、最小聚焦的光束轮廓，具有超声作用 模拟压力振幅上限的参数 来自临床超声成像和多普勒系统。 重点 将被放在提供可复制的， 超声输送和生物测定。